## PROPARACAINE HYDROCHLORIDE- proparacaine hydrochloride solution/ drops

NuCare Pharmaceuticals, Inc.

\_\_\_\_\_

Proparacaine Hydrochloride


Ophthalmic Solution USP, 0.5%

# DESCRIPTION

Proparacaine hydrochloride ophthalmic solution 0.5% is a topical local anesthetic for ophthalmic use. The active ingredient is represented by the structural formula:

Established name: Proparacaine Hydrochloride

Chemical name: Benzoic acid, 3-amino-4-propoxy-,2-(diethylamino) ethyl ester, monohydrochloride.



Molecular Weight: 330.85

Each mL contains: **Active:** proparacaine hydrochloride 5mg 0.5%. **Preservative:** benzalkonium chloride (0.01%). **Inactives:** glycerin; and purified water. The pH may be adjusted with hydrochloric acid and/or sodium hydroxide.

# **CLINICAL PHARMACOLOGY**

Proparacaine hydrochloride ophthalmic solution is a rapidly-acting topical anesthetic, with induced anesthesia lasting approximately 10-20 minutes.

# INDICATIONS AND USAGE

Proparacaine hydrochloride ophthalmic solution is indicated for procedures in which a topical ophthalmic anesthetic is indicated: corneal anesthesia of short duration, e.g. tonometry, gonioscopy, removal of corneal foreign bodies, and for short corneal and conjunctival procedures.

#### CONTRAINDICATIONS

Proparacaine hydrochloride ophthalmic solution should be considered contraindicated in patients with known hypersensitivity to any of the ingredients of this preparation.

#### WARNINGS

NOT FOR INJECTION - FOR TOPICAL OPHTHALMIC USE ONLY. Prolonged use of a topical ocular anesthetic is not recommended. It may produce permanent corneal opacification with accompanying visual loss.

## PRECAUTIONS

#### Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies in animals have not been performed to evaluate carcinogenic potential, mutagenicity, or possible impairment of fertility in males or females.

#### Pregnancy

Pregnancy Category C: Animal reproduction studies have not been conducted with proparacaine hydrochloride ophthalmic solution 0.5%. It is also not known whether proparacaine hydrochloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Proparacaine hydrochloride should be administered to a pregnant woman only if clearly needed.

#### **Nursing Mothers**

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when proparacaine hydrochloride is administered to a nursing woman.

#### **Pediatric Use**

Safety and effectiveness of proparacaine hydrochloride ophthalmic solution in pediatric patients have been established. Use of proparacaine hydrochloride is supported by evidence from adequate and well-controlled studies in adults and children over the age of twelve, and safety information in neonates and other pediatric patients.

#### Geriatric Use

No overall clinical differences in safety or effectiveness have been observed between the elderly and other adult patients

#### **ADVERSE REACTIONS**

Occasional temporary stinging, burning and conjunctival redness may occur with the use of proparacaine. A rare, severe, immediate-type, apparently hyperallergic corneal reaction characterized by acute, intense and diffuse epithelial keratitis, a gray, ground glass appearance, sloughing of large areas of necrotic epithelium, corneal filaments and, sometimes, iritis with descemetitis has been reported.

Allergic contact dermatitis from proparacaine with drying and fissuring of the fingertips has also been reported.

# DOSAGE AND ADMINISTRATION

**Usual Dosage:** Removal of foreign bodies and sutures, and for tonometry: 1 to 2 drops (in single instillations) in each eye before operating.

Short corneal and conjunctival procedures: 1 drop in each eye every 5 to 10 minutes for 5 to 7 doses.

**NOTE:** Proparacaine hydrochloride ophthalmic solution should be clear to straw-color. If the solution becomes darker, discard the solution.

## HOW SUPPLIED

Proparacaine hydrochloride ophthalmic solution 0.5% is supplied in 15 mL DROP-TAINER\* dispensers.

NDC 68071-4701-5

**Storage:** Bottle must be stored in unit carton to protect contents from light. Store bottles under refrigeration at 2° - 8°C (36° - 46°F).

#### **Rx Only**

To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc., at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

\*DROP-TAINER is a registered trademark of Alcon Research, Ltd.


Rev. June 2012

# SANDOZ

Manufactured by Alcon Laboratories, Inc. Fort Worth, Texas 76134 for Sandoz Inc. Princeton, NJ 08540 Printed in USA

#### 9007253-1011

PRINCIPAL DISPLAY PANEL



DI			ROCHLORIDE				
	oparacaine hyd						
pro		arochionae s					
Ρ	roduct Infor	rmation					
P	roduct Type		HUMAN PRESCRIPTION DRUG	ltem Code (Source)	NDC:680 016)	)71-4701(N	IDC:61314-
R	oute of Admin	istration	OPHTHALMIC				
A	ctive Ingred	ient/Active	Moiety				
		Ingre	dient Name		Basis of St	rength	Strength
				PROPARACAINE HYDROCHLORIDE		5 mg in 1 mL	
In	active Ingre	edients					
Ingredient Name						Strength	
BENZALKONIUM CHLORIDE (UNII: F5UM2KM3W7)							
GLYCERIN (UNII: PDC6A3C0OX)							
WATER (UNII: 059QF0KO0R)							
HYDROCHLORIC ACID (UNII: QTT17582CB)							
sc	DDIUM HYDROX	IDE (UNII: 55X04	QC32I)				
_							
Pa	ackaging						
		Da	ckage Description	Marl	ceting Start		ting End
#	Item Code	Pa			Date	D	ate

Marketing Information									
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date						
ANDA	ANDA080027	06/05/2000							

Labeler - NuCare Pharmaceuticals,Inc. (010632300)

# Establishment

Name	Address	ID/FEI	<b>Business Operations</b>
NuCare Pharmaceuticals, Inc.		010632300	relabel(68071-4701)

Revised: 2/2021

NuCare Pharmaceuticals, Inc.